Bolt Biotherapeutics, Inc.
BOLT
$4.54
-$0.10-2.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 15.26% | 20.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.26% | 20.23% | |||
| Cost of Revenue | -23.67% | -12.84% | |||
| Gross Profit | 43.01% | 23.32% | |||
| SG&A Expenses | -6.59% | -5.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.90% | -10.37% | |||
| Operating Income | 27.24% | 16.36% | |||
| Income Before Tax | 7.18% | 16.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.18% | 16.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.18% | 16.55% | |||
| EBIT | 27.24% | 16.36% | |||
| EBITDA | 27.83% | 16.36% | |||
| EPS Basic | -3.15% | 16.63% | |||
| Normalized Basic EPS | 19.87% | 16.63% | |||
| EPS Diluted | -3.15% | 16.63% | |||
| Normalized Diluted EPS | 19.87% | 16.63% | |||
| Average Basic Shares Outstanding | -10.01% | 0.09% | |||
| Average Diluted Shares Outstanding | -10.01% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||